Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interstitial pregnancy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    88 result(s) found for: Interstitial pregnancy. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2015-004495-30 Sponsor Protocol Number: CYCLOIC-1 Start Date*: 2015-12-14
    Sponsor Name:Oulu University Hospital
    Full Title: Safety of intravesical bladder instillations among patients with severe interstitial cystitis
    Medical condition: Interstitial cystitis and bladder pain syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10071166 Bladder pain syndrome LLT
    18.1 10038359 - Renal and urinary disorders 10011796 Cystitis interstitial PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-005103-39 Sponsor Protocol Number: AP01-005 Start Date*: 2021-04-16
    Sponsor Name:Avalyn Pharma, Inc.
    Full Title: Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis
    Medical condition: Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003584-18 Sponsor Protocol Number: KKS-307 Start Date*: 2023-06-26
    Sponsor Name:Philipps University Marburg
    Full Title: Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia
    Medical condition: Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022619 Interstitial pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000861-32 Sponsor Protocol Number: KKS-206 Start Date*: 2015-12-01
    Sponsor Name:Justus Liebig Universität Giessen
    Full Title: Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) A randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial
    Medical condition: 1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10022612 Interstitial lung fibrosis LLT
    20.0 100000004855 10035754 Pneumonitis hypersensitivity LLT
    20.0 100000004855 10025088 Lung fibrosis LLT
    20.0 100000004855 10022617 Interstitial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003367-23 Sponsor Protocol Number: 672-CL-035 Start Date*: 2006-02-13
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis
    Medical condition: Interstitial Cystitis / Painful Bladder Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008928 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-002421-37 Sponsor Protocol Number: A4291043 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
    Full Title: A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS...
    Medical condition: INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008927 Chronic interstitial cystitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) FR (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-014597-17 Sponsor Protocol Number: A4091035 Start Date*: 2010-05-03
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIA...
    Medical condition: Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008927 Chronic interstitial cystitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) DE (Prematurely Ended) FI (Completed) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000906-12 Sponsor Protocol Number: AQX-1125-301 Start Date*: 2016-09-07
    Sponsor Name:Aquinox Pharmaceuticals (Canada) Inc.
    Full Title: The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targ...
    Medical condition: Interstitial Cystitis/Bladder Pain Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10071166 Bladder pain syndrome LLT
    20.0 100000004857 10008927 Chronic interstitial cystitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Completed) CZ (Completed) LV (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001741-18 Sponsor Protocol Number: AC-052-322 Start Date*: 2008-06-24
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IE (Completed) BE (Completed) AT (Completed) GB (Completed) CZ (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018118-21 Sponsor Protocol Number: OXN2503 Start Date*: Information not available in EudraCT
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to place...
    Medical condition: Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10008927 Chronic interstitial cystitis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024211-13 Sponsor Protocol Number: AC-055B202 Start Date*: 2011-05-26
    Sponsor Name:ACTELION Pharmaceuticals Ltd.
    Full Title: Long term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis
    Medical condition: Patients with Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Prematurely Ended) SI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004405-34 Sponsor Protocol Number: GS-US-231-0101 Start Date*: 2010-09-13
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmon...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024332-42 Sponsor Protocol Number: BAY63-2521/13605 Start Date*: 2014-04-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon...
    Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001183-24 Sponsor Protocol Number: AC-052-321 Start Date*: 2007-03-06
    Sponsor Name:ACTELION PHARMACEUTICALS LTD
    Full Title: Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequ...
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) IE (Completed) GB (Completed) FR (Completed) DE (Completed) AT (Completed) DK (Completed) CZ (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002305-38 Sponsor Protocol Number: 2013CV11 Start Date*: 2015-01-21
    Sponsor Name:University of Dundee/ NHS Tayside
    Full Title: Does allopurinol reduce right ventricular mass in lung disease associated pulmonary hypertension?
    Medical condition: right ventricular hypertrophy associated with COPD or Interstitial Lung Disease and pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    17.1 10007541 - Cardiac disorders 10050326 Right ventricular hypertrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000564-14 Sponsor Protocol Number: PIPF-023 Start Date*: 2013-06-18
    Sponsor Name:InterMune International AG.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenid...
    Medical condition: Patients with Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) IT (Completed) AT (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005881-17 Sponsor Protocol Number: RIN-PF-303 Start Date*: 2022-08-18
    Sponsor Name:UNITED THERAPEUTICS CORPORATION
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005554-23 Sponsor Protocol Number: 1199-0378 Start Date*: 2021-11-24
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 2 years, in children and adolescents with clinically significant fibrosi...
    Medical condition: Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066393 Respiratory bronchiolitis-associated interstitial lung disease LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Prematurely Ended) BE (Trial now transitioned) NL (Ongoing) GR (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) FI (Completed) DK (Ongoing) IT (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004530-14 Sponsor Protocol Number: 1199-0337 Start Date*: 2019-10-15
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with nin...
    Medical condition: Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066393 Respiratory bronchiolitis-associated interstitial lung disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Completed) FI (Completed) NO (Completed) DK (Completed) FR (Completed) CZ (Completed) PL (Completed) GR (Completed) HU (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001281-86 Sponsor Protocol Number: CNTO888PUL2001 Start Date*: 2009-01-14
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in ...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 02:06:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA